In the SEZ "Kaluga" will be the Russian company "Miraxpharma"
On 19 December signed an agreement of intent between the Government of Kaluga region and JSC "Miraxpharma" in the sphere of realization of investment project of construction of a plant for the production of non-sterile medicinal products and substances in the region. Signatures under the corresponding document was signed: the Governor of Kaluga region Anatoly Artamonov and the President of the company "Miraksfarma" Michael Fingers.
Under the agreement reached a preliminary agreement to build a new enterprise on the territory of the special economic zone of industrial-production type "Kaluga". The company was chosen as the site of the SEZ with an area of 6.8 hectares, located in Borovsk district. The volume of investments will amount to 3 billion rubles, the number of jobs created – approximately 480.
The plant will produce pharmaceutical substances and finished medicinal products to solve problems in the field of women's and men's reproductive health and oncoprophylaxis. The company is a developer and manufacturer of innovative non-hormonal drugs used in the treatment of mastitis, uterine fibroids, human papillomavirus infection, and also to prevent breast cancer and ovarian, cervical cancer and other diseases. The products are manufactured according to GMP standards. Markets – the territory of the Russian Federation and the countries of the customs Union.
JSC "Miraxpharma" – a modern company of a new generation of Russian producers, building their businesses in accordance with the latest trends in the pharmaceutical market to meet current standards of quality and management.
Michael Finger: "Our project is not only a production complex with complete production cycle of drugs, but also a part of the own development and implementation, medical Department, promotion Department and marketing. The new facility will create a unique scientific – production complex on development and introduction of modern drugs, including not having analogues. We expect that our production capacity will exceed 1 billion units of finished products per year."
In turn, Anatoly Artamonov stressed that the Kaluga pharmaceutical cluster has arrived the new party. "Russian farmproekt will attract in Kaluga oblast a new technology and competence", commented Anatoly Artamonov.
Pharmaceutical enterprises of the region produce about 139 items in the promising development of several dozens. More than 80% of the production of cluster – ready medical products, 19 billion rubles – the volume produced in 2015 products.
In October of this year, the Kaluga pharmaceutical cluster has become a party to a priority project of the Ministry of economic development "innovation clusters – leaders of investment attractiveness of world level".
Additionally
Cluster "Pharmaceutics, biotechnologies and Biomedicine" Kaluga region formed in 2011. In 2012, legally in the form of non-commercial partnership "Kaluga pharmaceutical cluster" (NK "KFK").
Industry specialization – conducting preclinical and clinical trials, development, synthesis and implementation in production of pharmaceutical substances and radiopharmaceuticals, industrial production of FPP and pharmaceutical substances, infusion solutions and parenteral nutrition.
Kaluga pharmaceutical cluster includes the largest international and Russian farmanara ("Hemofarm", "AstraZeneca", "nearmedic" "Novo Nordisk", "STADA SRL LLC", "BerlinChemie/Menarini"), medium and small innovative companies, leading research and educational centres — in total more than 60 participants.
Kaluga pharmaceutical cluster sets a strategic goal to be the three largest pharmaceutical clusters in Russia by market share. According to forecasts, by 2020 this proportion will reach 10-12%.
According to the results of the examination held in 2015 by the European Secretariat for Cluster Analysis (ESCA) among 750 clusters, only 5 of Russian clusters received the bronze certificate of Excellence Cluster, among them — Kaluga pharmaceutical cluster received the highest rating in the group Health and medical science. Evaluation activities were carried out in comparison with 19 leading European clusters corresponding profile.
In early November, within the framework of partnering-forum Meet in Italy for Life Sciences signed an agreement on cooperation between Kaluga pharmaceutical cluster and one of the largest in Italy cluster-C. H. I. C. O. (Cluster of Health, Innovation and Community). Assumes cooperation in a number of priority areas of the pharmaceutical industry clusters – exchange of experience in the research field, participation in joint projects, development of technology and production of original pharmaceutical substances.
